Ra Pharmaceuticals Stock Price, News & Analysis (NASDAQ:RARX)

$6.83 +0.04 (+0.59 %)
(As of 02/20/2018 02:18 PM ET)
Previous Close$6.83
Today's Range$6.68 - $7.34
52-Week Range$5.80 - $27.84
Volume191,800 shs
Average Volume205,203 shs
Market Capitalization$154.54 million
P/E RatioN/A
Dividend YieldN/A
Beta2.15

About Ra Pharmaceuticals (NASDAQ:RARX)

Ra Pharmaceuticals logoRa Pharmaceuticals, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade. It has leveraged the Extreme Diversity peptide chemistry platform to develop a portfolio of products that selectively inhibit the complement system and other immune targets. Its main program, RA101495, is a macrocyclic peptide inhibitor of complement component 5 (C5), which is in Phase I stage of development for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). RA101495 binds a site on the C5 protein to inhibit cleavage into C5a and C5b, thereby preventing red blood cell lysis by inhibiting the production and assembly of the membrane attack complex (MAC). RA101495 is being developed as an alternative to eculizumab therapy for patients with PNH.

Receive RARX News and Ratings via Email

Sign-up to receive the latest news and ratings for RARX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:RARX
CUSIPN/A
Phone617-401-4060

Debt

Debt-to-Equity RatioN/A
Current Ratio10.92%
Quick Ratio10.92%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$4.93 million
Price / Sales31.35
Cash FlowN/A
Price / CashN/A
Book Value$5.20 per share
Price / Book1.31

Profitability

Trailing EPS($2.47)
Net Income$-28,860,000.00
Net MarginsN/A
Return on Equity-49.83%
Return on Assets-45.57%

Miscellaneous

Employees46
Outstanding Shares22,630,000

Ra Pharmaceuticals (NASDAQ:RARX) Frequently Asked Questions

What is Ra Pharmaceuticals' stock symbol?

Ra Pharmaceuticals trades on the NASDAQ under the ticker symbol "RARX."

How were Ra Pharmaceuticals' earnings last quarter?

Ra Pharmaceuticals Inc (NASDAQ:RARX) posted its quarterly earnings data on Thursday, November, 9th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.62) by $0.06. View Ra Pharmaceuticals' Earnings History.

When will Ra Pharmaceuticals make its next earnings announcement?

Ra Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March, 5th 2018. View Earnings Estimates for Ra Pharmaceuticals.

Where is Ra Pharmaceuticals' stock going? Where will Ra Pharmaceuticals' stock price be in 2018?

4 brokers have issued 12 month target prices for Ra Pharmaceuticals' shares. Their predictions range from $14.00 to $34.00. On average, they anticipate Ra Pharmaceuticals' stock price to reach $22.75 in the next twelve months. View Analyst Ratings for Ra Pharmaceuticals.

Who are some of Ra Pharmaceuticals' key competitors?

Who are Ra Pharmaceuticals' key executives?

Ra Pharmaceuticals' management team includes the folowing people:

  • Douglas A. Treco Ph.D., President, Chief Executive Officer, Co-Founder, Director
  • Jeffrey Johnston M.D., Senior Vice President, Chief Medical Officer
  • Alonso Ricardo Ph.D., Senior Vice President of Research & Development
  • Kerry Black, Executive Director, Operations
  • Edward T. Mathers, Board Member (Age 57)

When did Ra Pharmaceuticals IPO?

(RARX) raised $75 million in an IPO on Wednesday, October 26th 2016. The company issued 5,800,000 shares at a price of $12.00-$14.00 per share. Credit Suisse, Jefferies and BMO Capital Markets acted as the underwriters for the IPO and SunTrust Robinson Humphrey was co-manager.

Who owns Ra Pharmaceuticals stock?

Ra Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (4.21%), VHCP Management II LLC (2.41%), Millennium Management LLC (1.97%), Tekla Capital Management LLC (1.57%), Citadel Advisors LLC (1.32%) and Candriam Luxembourg S.C.A. (0.67%). Company insiders that own Ra Pharmaceuticals stock include Bioventures Ltd Novartis, Harry R Weller, Ra Capital Healthcare Fund Lp and Rajeev M Shah. View Institutional Ownership Trends for Ra Pharmaceuticals.

Who sold Ra Pharmaceuticals stock? Who is selling Ra Pharmaceuticals stock?

Ra Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including VHCP Management II LLC, Millennium Management LLC, Tekla Capital Management LLC, Citadel Advisors LLC and Fred Alger Management Inc.. View Insider Buying and Selling for Ra Pharmaceuticals.

Who bought Ra Pharmaceuticals stock? Who is buying Ra Pharmaceuticals stock?

Ra Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Candriam Luxembourg S.C.A., Ellington Management Group LLC, Two Sigma Investments LP, Paloma Partners Management Co and Goldman Sachs Group Inc.. Company insiders that have bought Ra Pharmaceuticals stock in the last two years include Harry R Weller, Ra Capital Healthcare Fund Lp and Rajeev M Shah. View Insider Buying and Selling for Ra Pharmaceuticals.

How do I buy Ra Pharmaceuticals stock?

Shares of Ra Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ra Pharmaceuticals' stock price today?

One share of Ra Pharmaceuticals stock can currently be purchased for approximately $6.83.

How big of a company is Ra Pharmaceuticals?

Ra Pharmaceuticals has a market capitalization of $154.54 million and generates $4.93 million in revenue each year. The company earns $-28,860,000.00 in net income (profit) each year or ($2.47) on an earnings per share basis. Ra Pharmaceuticals employs 46 workers across the globe.

How can I contact Ra Pharmaceuticals?

Ra Pharmaceuticals' mailing address is 87 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA, 02140. The company can be reached via phone at 617-401-4060 or via email at [email protected]


MarketBeat Community Rating for Ra Pharmaceuticals (RARX)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  100 (Vote Outperform)
Underperform Votes:  85 (Vote Underperform)
Total Votes:  185
MarketBeat's community ratings are surveys of what our community members think about Ra Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Ra Pharmaceuticals (NASDAQ:RARX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $22.75$23.25$25.00$26.75
Price Target Upside: 255.47% upside186.68% upside76.93% upside67.92% upside

Ra Pharmaceuticals (NASDAQ:RARX) Consensus Price Target History

Price Target History for Ra Pharmaceuticals (NASDAQ:RARX)

Ra Pharmaceuticals (NASDAQ:RARX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/13/2018Credit Suisse GroupLower Price TargetOutperform -> Outperform$16.00 -> $14.00MediumView Rating Details
12/5/2017Royal Bank of CanadaReiterated RatingBuy$18.00HighView Rating Details
12/5/2017BMO Capital MarketsBoost Price TargetHighView Rating Details
9/28/2017Jefferies GroupReiterated RatingBuy$25.00MediumView Rating Details
11/21/2016SunTrust BanksInitiated CoverageBuy$32.00N/AView Rating Details
(Data available from 2/20/2016 forward)

Earnings

Ra Pharmaceuticals (NASDAQ:RARX) Earnings History and Estimates Chart

Earnings by Quarter for Ra Pharmaceuticals (NASDAQ:RARX)

Ra Pharmaceuticals (NASDAQ RARX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/5/2018        
11/9/2017Q3 2017($0.62)($0.68)ViewN/AView Earnings Details
8/9/2017Q2 2017($0.50)($0.56)ViewN/AView Earnings Details
5/11/2017Q1 2017($0.58)($0.50)ViewN/AView Earnings Details
3/6/2017Q4 2016($0.44)($0.73)ViewN/AView Earnings Details
11/29/2016Q3 2016($0.50)($14.22)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Ra Pharmaceuticals (NASDAQ:RARX) Earnings Estimates

2018 EPS Consensus Estimate: ($3.75)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.77)($0.77)($0.77)
Q2 20181($0.91)($0.91)($0.91)
Q3 20181($0.93)($0.93)($0.93)
Q4 20181($1.14)($1.14)($1.14)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Ra Pharmaceuticals (NASDAQ:RARX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Ra Pharmaceuticals (NASDAQ RARX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 14.50%
Institutional Ownership Percentage: 70.27%
Insider Trades by Quarter for Ra Pharmaceuticals (NASDAQ:RARX)
Institutional Ownership by Quarter for Ra Pharmaceuticals (NASDAQ:RARX)

Ra Pharmaceuticals (NASDAQ RARX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/14/2018Ra Capital Healthcare Fund LpMajor ShareholderBuy2,500,000$6.00$15,000,000.00View SEC Filing  
6/19/2017Bioventures Ltd NovartisMajor ShareholderSell56,420$21.29$1,201,181.80View SEC Filing  
6/7/2017Bioventures Ltd NovartisMajor ShareholderSell12,114$22.63$274,139.82View SEC Filing  
6/5/2017Bioventures Ltd NovartisMajor ShareholderSell19,647$23.38$459,346.86View SEC Filing  
6/1/2017Bioventures Ltd NovartisMajor ShareholderSell46,261$23.93$1,107,025.73View SEC Filing  
5/26/2017Bioventures Ltd NovartisMajor ShareholderSell5,353$25.14$134,574.42View SEC Filing  
5/24/2017Bioventures Ltd NovartisMajor ShareholderSell17,451$25.01$436,449.51View SEC Filing  
5/18/2017Bioventures Ltd NovartisMajor ShareholderSell9,019$25.50$229,984.50View SEC Filing  
5/17/2017Bioventures Ltd NovartisMajor ShareholderSell42,615$25.90$1,103,728.50View SEC Filing  
10/31/2016Harry R WellerMajor ShareholderBuy338,462$13.00$4,400,006.00View SEC Filing  
10/31/2016Rajeev M ShahDirectorBuy161,538$13.00$2,099,994.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Ra Pharmaceuticals (NASDAQ RARX) News Headlines

Source:
DateHeadline
Ra Capital Healthcare Fund Lp Buys 2,500,000 Shares of Ra Pharmaceuticals Inc (RARX) StockRa Capital Healthcare Fund Lp Buys 2,500,000 Shares of Ra Pharmaceuticals Inc (RARX) Stock
www.americanbankingnews.com - February 16 at 9:08 PM
Ra Pharmaceuticals (RARX) Prices 8.4M Common Stock Offering at $6/ShareRa Pharmaceuticals (RARX) Prices 8.4M Common Stock Offering at $6/Share
www.streetinsider.com - February 15 at 4:27 PM
Ra Pharmaceuticals to Present at the RBC Capital Markets 2018 Global Healthcare ConferenceRa Pharmaceuticals to Present at the RBC Capital Markets 2018 Global Healthcare Conference
finance.yahoo.com - February 15 at 8:52 AM
Ra Pharmaceuticals Announces Pricing of Public Offering of Common StockRa Pharmaceuticals Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - February 14 at 4:41 PM
Ra Pharmaceuticals Announces Proposed Public Offering of Common StockRa Pharmaceuticals Announces Proposed Public Offering of Common Stock
finance.yahoo.com - February 14 at 9:02 AM
Ra Pharmaceuticals (RARX) Price Target Cut to $14.00Ra Pharmaceuticals (RARX) Price Target Cut to $14.00
www.americanbankingnews.com - February 13 at 11:44 AM
Ra Pharmaceuticals (RARX) & Pieris Pharmaceuticals (PIRS) Head-To-Head ReviewRa Pharmaceuticals (RARX) & Pieris Pharmaceuticals (PIRS) Head-To-Head Review
www.americanbankingnews.com - February 10 at 7:24 AM
Ra Pharmaceuticals (RARX) Downgraded to "Strong Sell" at ValuEngineRa Pharmaceuticals (RARX) Downgraded to "Strong Sell" at ValuEngine
www.americanbankingnews.com - February 4 at 3:56 PM
Ra Pharmaceuticals Inc (RARX) Given Consensus Rating of "Buy" by BrokeragesRa Pharmaceuticals Inc (RARX) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - February 2 at 1:36 AM
Credit Suisse Group Reiterates Outperform Rating for Ra Pharmaceuticals (RARX)Credit Suisse Group Reiterates Outperform Rating for Ra Pharmaceuticals (RARX)
www.americanbankingnews.com - January 21 at 5:34 PM
Zacks: Brokerages Expect Ra Pharmaceuticals Inc (RARX) Will Announce Earnings of -$0.72 Per ShareZacks: Brokerages Expect Ra Pharmaceuticals Inc (RARX) Will Announce Earnings of -$0.72 Per Share
www.americanbankingnews.com - January 17 at 5:12 PM
Ra Pharmaceuticals Inc (RARX) Short Interest Up 41.2% in DecemberRa Pharmaceuticals Inc (RARX) Short Interest Up 41.2% in December
www.americanbankingnews.com - January 14 at 2:32 AM
Ra Pharmaceuticals Initiates Dosing in Phase 1b Pharmacokinetic Study Evaluating RA101495 SC in Patients with Renal ImpairmentRa Pharmaceuticals Initiates Dosing in Phase 1b Pharmacokinetic Study Evaluating RA101495 SC in Patients with Renal Impairment
finance.yahoo.com - January 8 at 10:56 AM
Analyzing Ra Pharmaceuticals (RARX) and Its CompetitorsAnalyzing Ra Pharmaceuticals (RARX) and Its Competitors
www.americanbankingnews.com - January 1 at 9:10 PM
Analyzing Ra Pharmaceuticals (RARX) & Its CompetitorsAnalyzing Ra Pharmaceuticals (RARX) & Its Competitors
www.americanbankingnews.com - December 30 at 5:20 AM
Ra Pharmaceuticals Initiates Dosing in Phase 2 Clinical Trial Evaluating RA101495 SC in Generalized Myasthenia Gravis PatientsRa Pharmaceuticals Initiates Dosing in Phase 2 Clinical Trial Evaluating RA101495 SC in Generalized Myasthenia Gravis Patients
finance.yahoo.com - December 21 at 4:17 PM
Analyzing Ra Pharmaceuticals (RARX) and Its RivalsAnalyzing Ra Pharmaceuticals (RARX) and Its Rivals
www.americanbankingnews.com - December 20 at 9:28 PM
Ra Pharmaceuticals Inc (RARX) Expected to Post Earnings of -$0.72 Per ShareRa Pharmaceuticals Inc (RARX) Expected to Post Earnings of -$0.72 Per Share
www.americanbankingnews.com - December 15 at 3:10 AM
Ra Pharmaceuticals (RARX) versus Its Competitors Head-To-Head ComparisonRa Pharmaceuticals (RARX) versus Its Competitors Head-To-Head Comparison
www.americanbankingnews.com - December 14 at 5:30 AM
Ra Pharmaceuticals to Present at the BMO Capital Markets Prescriptions for Success Healthcare ConferenceRa Pharmaceuticals to Present at the BMO Capital Markets Prescriptions for Success Healthcare Conference
finance.yahoo.com - December 7 at 11:09 AM
Ra Pharmaceuticals (RARX) vs. The Competition Financial AnalysisRa Pharmaceuticals (RARX) vs. The Competition Financial Analysis
www.americanbankingnews.com - December 6 at 7:52 AM
Ra Pharmaceuticals (RARX) Given "Buy" Rating at Royal Bank Of CanadaRa Pharmaceuticals (RARX) Given "Buy" Rating at Royal Bank Of Canada
www.americanbankingnews.com - December 6 at 12:26 AM
Ra Pharmaceuticals IncRa Pharmaceuticals Inc
www.bloomberg.com - December 5 at 12:28 PM
Why Ra Pharmaceuticals, Inc. Got Hammered TodayWhy Ra Pharmaceuticals, Inc. Got Hammered Today
finance.yahoo.com - December 5 at 12:28 PM
Ra Pharmaceuticals (RARX) Given New $0.00 Price Target at BMO Capital MarketsRa Pharmaceuticals (RARX) Given New $0.00 Price Target at BMO Capital Markets
www.americanbankingnews.com - December 5 at 9:46 AM
Ra Pharmaceuticals (RARX) Reports Positive Interim Results from Phase 2 Study of RA101495 SC in PNHRa Pharmaceuticals (RARX) Reports Positive Interim Results from Phase 2 Study of RA101495 SC in PNH
www.streetinsider.com - December 4 at 4:12 PM
Ra Pharmaceuticals (RARX) Rating Reiterated by BMO Capital MarketsRa Pharmaceuticals (RARX) Rating Reiterated by BMO Capital Markets
www.americanbankingnews.com - December 4 at 12:30 PM
Comparing Ra Pharmaceuticals (RARX) & Coherus BioSciences (CHRS)Comparing Ra Pharmaceuticals (RARX) & Coherus BioSciences (CHRS)
www.americanbankingnews.com - November 27 at 9:32 PM
Ra Pharmctl (RARX) and Axovant Sciences (AXON) Head to Head ReviewRa Pharmctl (RARX) and Axovant Sciences (AXON) Head to Head Review
www.americanbankingnews.com - November 21 at 12:06 PM
Ra Pharmctl Inc (RARX) Downgraded by Zacks Investment Research to HoldRa Pharmctl Inc (RARX) Downgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - November 15 at 7:15 AM
Ra Pharmctl Inc (RARX) Sees Significant Drop in Short InterestRa Pharmctl Inc (RARX) Sees Significant Drop in Short Interest
www.americanbankingnews.com - November 14 at 2:56 AM
Brokers Issue Forecasts for Ra Pharmctl Incs Q1 2018 Earnings (RARX)Brokers Issue Forecasts for Ra Pharmctl Inc's Q1 2018 Earnings (RARX)
www.americanbankingnews.com - November 13 at 5:40 AM
Ra Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate UpdateRa Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - November 12 at 12:06 PM
Ra Pharmctl Inc (RARX) PT Raised to $23.00Ra Pharmctl Inc (RARX) PT Raised to $23.00
www.americanbankingnews.com - November 10 at 5:42 PM
Ra Pharmctl Inc (RARX) Issues Quarterly  Earnings Results, Misses Estimates By $0.06 EPSRa Pharmctl Inc (RARX) Issues Quarterly Earnings Results, Misses Estimates By $0.06 EPS
www.americanbankingnews.com - November 10 at 2:57 PM
Ra Pharmctl Inc (RARX) Expected to Post Earnings of -$0.74 Per ShareRa Pharmctl Inc (RARX) Expected to Post Earnings of -$0.74 Per Share
www.americanbankingnews.com - November 8 at 9:51 AM
Ra Pharmctl Inc (RARX) Given Consensus Recommendation of "Buy" by AnalystsRa Pharmctl Inc (RARX) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - November 3 at 5:46 AM
Ra Pharmaceuticals to Present at Upcoming Investor ConferencesRa Pharmaceuticals to Present at Upcoming Investor Conferences
finance.yahoo.com - October 31 at 8:29 AM
Zacks Investment Research Upgrades Ra Pharmctl Inc (RARX) to "Hold"Zacks Investment Research Upgrades Ra Pharmctl Inc (RARX) to "Hold"
www.americanbankingnews.com - October 11 at 10:30 AM
Ra Pharmctl Inc (RARX) Given Average Rating of "Buy" by BrokeragesRa Pharmctl Inc (RARX) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - October 9 at 2:42 AM
-$0.74 Earnings Per Share Expected for Ra Pharmaceuticals Inc (RARX) This Quarter-$0.74 Earnings Per Share Expected for Ra Pharmaceuticals Inc (RARX) This Quarter
www.americanbankingnews.com - September 30 at 6:14 PM
Ra Pharmctls (RARX) Buy Rating Reaffirmed at Jefferies Group LLCRa Pharmctl's (RARX) Buy Rating Reaffirmed at Jefferies Group LLC
www.americanbankingnews.com - September 28 at 8:00 AM
Ra Pharmaceuticals to Present at the Cantor Fitzgerald Global Healthcare ConferenceRa Pharmaceuticals to Present at the Cantor Fitzgerald Global Healthcare Conference
finance.yahoo.com - September 20 at 8:14 AM
Ra Pharmctl Inc (RARX) Given Average Recommendation of "Buy" by BrokeragesRa Pharmctl Inc (RARX) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - September 14 at 6:50 PM
Ra Pharmctl Inc (RARX) Research Coverage Started at Royal Bank Of CanadaRa Pharmctl Inc (RARX) Research Coverage Started at Royal Bank Of Canada
www.americanbankingnews.com - September 14 at 5:26 PM
Ra Pharmctl Inc (RARX) Given a $25.00 Price Target at Jefferies Group LLCRa Pharmctl Inc (RARX) Given a $25.00 Price Target at Jefferies Group LLC
www.americanbankingnews.com - August 26 at 8:16 AM
Q3 2017 Earnings Estimate for Ra Pharmctl Inc Issued By SunTrust Banks (NASDAQ:RARX)Q3 2017 Earnings Estimate for Ra Pharmctl Inc Issued By SunTrust Banks (NASDAQ:RARX)
www.americanbankingnews.com - August 14 at 2:28 AM
Ra Pharmctl Inc (RARX) Releases Quarterly  Earnings Results, Misses Expectations By $0.06 EPSRa Pharmctl Inc (RARX) Releases Quarterly Earnings Results, Misses Expectations By $0.06 EPS
www.americanbankingnews.com - August 11 at 12:40 AM
Ra Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate UpdateRa Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - August 10 at 7:17 AM
Ra Pharmaceuticals Receives Orphan Drug Designation from the U.S. FDA for RA101495 for the Treatment of Paroxysmal Nocturnal HemoglobinuriaRa Pharmaceuticals Receives Orphan Drug Designation from the U.S. FDA for RA101495 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria
finance.yahoo.com - August 1 at 5:19 AM

SEC Filings

Ra Pharmaceuticals (NASDAQ:RARX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Ra Pharmaceuticals (NASDAQ:RARX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Ra Pharmaceuticals (NASDAQ RARX) Stock Chart for Tuesday, February, 20, 2018

Loading chart…

This page was last updated on 2/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.